Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.59, in-line with the analyst estimate of $0.59. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.48 billion.

GUIDANCE:

Edwards Lifesciences sees Q4 2023 revenue of $1.45-1.53 billion, versus the consensus of $1.54 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.